Last reviewed · How we verify
actoplus met
Actoplus Met combines pioglitazone (a thiazolidinedione that increases insulin sensitivity) with metformin (a biguanide that reduces hepatic glucose production) to improve glycemic control in type 2 diabetes.
Actoplus Met combines pioglitazone (a thiazolidinedione that increases insulin sensitivity) with metformin (a biguanide that reduces hepatic glucose production) to improve glycemic control in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | actoplus met |
|---|---|
| Sponsor | The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
| Drug class | Thiazolidinedione/Biguanide combination |
| Target | PPAR-γ (pioglitazone component); Complex I of mitochondrial respiratory chain (metformin component) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Pioglitazone acts as a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, enhancing insulin sensitivity in muscle and adipose tissue. Metformin decreases hepatic glucose production and improves peripheral glucose uptake. Together, they address multiple pathophysiologic defects in type 2 diabetes through complementary mechanisms.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Edema
- Gastrointestinal disturbance
- Lactic acidosis (rare)
Key clinical trials
- The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD (PHASE4)
- Effects of Different Early Intensive Therapies on Long-term β-cell Function (PHASE4)
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke (PHASE2)
- ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment (PHASE2)
- Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes (PHASE3)
- Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver (PHASE3)
- Effects of Pioglitazone Combined With Metformin on Gonadal and Metabolic Profiles in Chinese Nonobese PCOS Patients. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |